Literature DB >> 20412187

Outcome and predictors of treatment failure in early post-surgical prosthetic joint infections due to Staphylococcus aureus treated with debridement.

F Vilchez1, J C Martínez-Pastor, S García-Ramiro, G Bori, F Maculé, J Sierra, L Font, J Mensa, A Soriano.   

Abstract

Experience with debridement and prosthesis retention in early prosthetic joint infections (PJI) due to Staphylococcus aureus is scarce. The present study aimed to evaluate the outcome and predictors of failure. Patients prospectively registered with an early PJI due to S. aureus and 2 years of follow-up were reviewed. Demographics, co-morbidity, type of implant, clinical manifestations, surgical treatment, antimicrobial therapy and outcome were recorded. Remission was defined when the patient had no symptoms of infection, the prosthesis was retained and C-reactive protein (CRP) was ≤ 1 mg/dL. Univariate and multivariate analysis were performed. Fifty-three patients with a mean ± SD age of 70 ± 10.8 years were reviewed. Thirty-five infections were on knee prosthesis and 18 were on hip prosthesis. The mean ± SD duration of intravenous and oral antibiotics was 10.6 ± 6.7 and 88 ± 45.9 days, respectively. After 2 years of follow-up, 40 (75.5%) patients were in remission. Variables independently associated with failure were the need for a second debridement (OR 20.4, 95% CI 2.3-166.6, p 0.006) and a CRP > 22 mg/dL (OR 9.8, 95% CI 1.5-62.5, p 0.01). The onset of the infection within the 25 days after joint arthroplasty was at the limit of significance (OR 8.3, 95% CI 0.8-85.6, p 0.07). Debridement followed by a short period of antibiotics is a reasonable treatment option in early PJI due to S. aureus. Predictors of failure were the need for a second debridement to control the infection a CRP > 22 mg/dL and the infection onset within the first 25 days after joint arthroplasty.
© 2010 The Authors. Journal Compilation © 2010 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Year:  2011        PMID: 20412187     DOI: 10.1111/j.1469-0691.2010.03244.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  31 in total

1.  Predictors of treatment outcome in prosthetic joint infections treated with prosthesis retention.

Authors:  Ari-Pekka Puhto; Teija Puhto; Tuukka Niinimäki; Pasi Ohtonen; Juhana Leppilahti; Hannu Syrjälä
Journal:  Int Orthop       Date:  2015-07-03       Impact factor: 3.075

2.  Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant.

Authors:  J Gómez; E Canovas; V Baños; L Martínez; E García; A Hernández-Torres; M Canteras; J Ruiz; M Medina; P Martínez; A Canovas; A Soriano; M Clavel
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

Review 3.  Role of Rifampin against Staphylococcal Biofilm Infections In Vitro, in Animal Models, and in Orthopedic-Device-Related Infections.

Authors:  Werner Zimmerli; Parham Sendi
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 4.  Can periprosthetic hip joint infections be successfully managed by debridement and prosthesis retention?

Authors:  Konstantinos Anagnostakos; Cornelia Schmitt
Journal:  World J Orthop       Date:  2014-07-18

Review 5.  Prosthetic joint infection.

Authors:  Aaron J Tande; Robin Patel
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

Review 6.  Risk Factors and Treatment Options for Failure of a Two-Stage Exchange.

Authors:  Lorenzo Fagotti; Jakub Tatka; Mauro Jose Costa Salles; Marcelo C Queiroz
Journal:  Curr Rev Musculoskelet Med       Date:  2018-09

Review 7.  What is the evidence base to guide surgical treatment of infected hip prostheses? systematic review of longitudinal studies in unselected patients.

Authors:  Andrew D Beswick; Karen T Elvers; Alison J Smith; Rachael Gooberman-Hill; Andrew Lovering; Ashley W Blom
Journal:  BMC Med       Date:  2012-02-16       Impact factor: 8.775

8.  GMI, an Immunomodulatory Peptide from Ganoderma microsporum, Restrains Periprosthetic Joint Infections via Modulating the Functions of Myeloid-Derived Suppressor Cells and Effector T Cells.

Authors:  Kuo-Ti Peng; Jiun-Liang Chen; Liang-Tseng Kuo; Pei-An Yu; Wei-Hsiu Hsu; Chiang-Wen Lee; Pey-Jium Chang; Tsung-Yu Huang
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

Review 9.  Outcome of Debridement, Antibiotics, and Implant Retention for Staphylococcal Hip and Knee Prosthetic Joint Infections, Focused on Rifampicin Use: A Systematic Review and Meta-Analysis.

Authors:  H Scheper; L M Gerritsen; B G Pijls; S A Van Asten; L G Visser; M G J De Boer
Journal:  Open Forum Infect Dis       Date:  2021-07-01       Impact factor: 3.835

Review 10.  Treatment of periprosthetic infections: an economic analysis.

Authors:  Daniel Hernández-Vaquero; Mariano Fernández-Fairen; Ana Torres; Ann M Menzie; José Manuel Fernández-Carreira; Antonio Murcia-Mazon; Enrique Guerado; Luis Merzthal
Journal:  ScientificWorldJournal       Date:  2013-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.